FORMAC Pharmaceuticals announces collaboration with W. R. Grace & Co.’s Discovery Sciences
FORMAC Pharmaceuticals NV announced that it has entered into a multiyear global strategic partnership with W. R. Grace & Co.’s Discovery Sciences to develop new silica based drug products.
FORMAC will be responsible for the discovery and preclinical development of new small molecule candidate drugs that may benefit from its unique silica based drug delivery approach. The alliance will make use of FORMAC´s proprietary high throughput screening platform for identification of optimal silica-drug combinations. W.R. Grace & Co will provide material expertise, scale-up and commercialization for new optimized materials for drug delivery.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.